Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/26202

Title: Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogs for patients at risk of renal failure after liver transplantation: a prospective single center cohort study
Authors: Bielen, Rob
Robaeys, Geert
Schelfhout, Sigrid
Monbaliu, Diethard
Van der Merwe, Schalk
Pirenne, Jacques
Nevens, Frederik
Issue Date: 2018
Citation: TRANSPLANT INTERNATIONAL, 31(5), p. 503-509
Abstract: Currently, nucleos(t)ide analogs (NAs) in monotherapy are favored as prophylaxis against hepatitis B recurrence after liver transplantation. However, in patients at risk of renal failure, renal safety of NAs is of concern. We investigated the safety and efficacy of subcutaneous (SC) hepatitis B immunoglobulins (HBIG) in monotherapy. This is a single-arm prospective trial in patients transplanted >1 year. We included 43 Caucasian patients. The majority was treated with calcineurin inhibitors, and several patients had other risk factors for renal impairment as well: diabetes mellitus (n = 10/43), arterial hypertension (n = 11/43), and hyperlipidemia (=10/43). At inclusion, 42% (n = 18) had chronic kidney disease grade 3a. All patients were switched from IV HBIG with or without NAs to SC HBIG without NAs. After one year, the targeted titer was lowered to 150 IU/l in patients with low risk of recurrence. Mean follow-up time was 36 +/- 5 months. None of the patients had a relapse of HBsAg or HBV DNA. The treatment was well tolerated, safe and the renal function remained unchanged both in patients with (n = 18) or without (n = 25) renal impairment at baseline. The mean HBsAb titer could be decreased from 343 +/- 163 to 199 +/- 81 IU/l in the low-risk group (n = 17) and 218 +/- 71 IU/l in the high-risk group (n = 26). In 86% (n = 37) doses, reductions were possible, which significantly lowered the cost of treatment. SC HBIG without NAs had a 100% success rate in the long-term prevention of HBsAg and HBV DNA reappearance, without deterioration of renal function.
Notes: Bielen, R (reprint author), Ziekenhuis Oost Limburg, Dept Gastroenterol & Hepatol, Schiepse Bos 6, B-3600 Genk, Belgium. rob.bielen@uhasselt.be
URI: http://hdl.handle.net/1942/26202
DOI: 10.1111/tri.13112
ISI #: 000430188200006
ISSN: 0934-0874
Category: A1
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version212.55 kBAdobe PDF
Peer-reviewed author version344.02 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.